# South Korea Companion Diagnostics Oncology Market > South Korea Companion Diagnostics Oncology Market Research Report By Technology (Next Generation Sequencing, Polymerase Chain Reaction, In Situ Hybridization, Immunohistochemistry), By Applications (Therapeutic Monitoring, Patient Stratification, Predictive Testing, Disease Diagnosis), By End-user (Hospitals, Diagnostic Laboratories, Research Institutions, Pharmaceutical Companies), and By Test Type (Genetic Tests, Protein Biomarker Tests, MicroRNA Tests, Pathological Analysis) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 7.38% - **2024:** $ 114.25 Million - **2025:** $ 122.68 Million - **2035:** $ 250.04 Million - **Key Players:** Roche (CH), Thermo Fisher Scientific (US), Abbott (US), Agilent Technologies (US), Illumina (US), Qiagen (DE), Myriad Genetics (US), Hologic (US), Guardant Health (US) **Report ID:** MRFR/MED/48451-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-korea-companion-diagnostics-oncology-market-50208 --- ## Market Summary ## **South Korea Companion Diagnostics Oncology Market Overview** As per MRFR analysis, the South Korea Companion Diagnostics Oncology Market Size was estimated at 133 (USD Million) in 2023.The South Korea Companion Diagnostics Oncology Market is expected to grow from 142.75(USD Million) in 2024 to 355.6 (USD Million) by 2035. The South Korea Companion Diagnostics Oncology Market CAGR (growth rate) is expected to be around 8.651% during the forecast period (2025 - 2035). **Key South Korea Companion Diagnostics Oncology Market Trends Highlighted** Numerous important market drivers have influenced the notable trends observed in the South Korean companion diagnostics oncology market. The main factor propelling the expansion of companion diagnostics is the rising incidence of cancer in South Korea, which has grown to be a significant public health concern. The South Korean government has taken steps to improve cancer prevention and treatment, which has created an atmosphere that is conducive to the development of novel diagnostic tools that can provide patients individualised treatment options. Complementary diagnostics that assist in identifying the best treatments based on individual genetic profiles are becoming more and more in demand as personalised medicine gains traction. Recent technological developments have resulted in the creation of increasingly complex diagnostic instruments that raise the effectiveness and precision of cancer treatment. Research and development activities in this area are being strengthened by the increasing cooperation between South Korean academic institutions and biotechnology corporations. These collaborations are essential for encouraging innovation and accelerating the release of novel diagnostic technologies. Opportunities to be investigated also include the possibility of advancing biomarker research and creating innovative treatments that complement the Ministry of Health and Welfare's national health strategies. Companion diagnostics companies have an opportunity to prosper due to South Korea's dedication to funding healthcare infrastructure and providing assistance to biotech start-ups. The focus on customized treatments and individualized care will continue to propel market trends in companion diagnostics oncology as the nation advances in its battle against cancer, making it a promising sector for South Korean investment and expansion. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **South Korea Companion Diagnostics Oncology Market Drivers** **Increasing Prevalence of Cancer in South Korea** The rising prevalence of cancer in South Korea is a significant driver for the South Korea Companion Diagnostics Oncology Market. According to the Korean National Cancer Center, approximately 250,000 new cancer cases are reported each year, reflecting a 12% increase over the past five years. This alarming trend has necessitated more personalized treatment plans and diagnostic tools that can guide the choice of targeted therapies. Major pharmaceutical companies such as Samsung Bioepis and Celltrion are influencing this market by developing companion diagnostics that align with their oncology drug offerings, thus improving patient outcomes and overall survival rates. The demand for effective diagnostic solutions is expected to increase further due to the aging population and lifestyle-related risk factors prevalent in South Korea. **Government Initiatives and Support** The South Korean government has been actively promoting the development and adoption of precision medicine and companion diagnostics within its healthcare system. Initiatives from the Ministry of Health and Welfare aim to improve patient access to innovative therapies and diagnostics, specifically in oncology. Policies such as funding for Research and Development (R&D) of genetic testing and companion diagnostics are designed to foster innovation in this sector. The government's focus on personalized medicine is further highlighted by the introduction of the 4th Basic Plan for Cancer Control, which outlines efforts to enhance cancer management through advanced diagnostic technologies. Such governmental support creates a conducive environment for the growth of the South Korea Companion Diagnostics Oncology Market. **Technological Advancements in Diagnostic Tools** Technological advancements in diagnostic tools are propelling the growth of the South Korea Companion Diagnostics Oncology Market. Innovations in DNA sequencing and biomarker identification have significantly enhanced the accuracy of companion diagnostics. For example, the development of next-generation sequencing technologies has made it possible to analyze multiple genetic variants quickly and cost-effectively, which is critical for selecting targeted therapies in oncology. Companies like Illumina and Roche are integrating cutting-edge technologies into their diagnostic offerings, providing healthcare professionals with reliable tools to tailor treatments for patients based on their genetic profiles. As these technological solutions become more accessible, it is expected that they will drive further demand for companion diagnostics in oncology across South Korea. **Growing Collaboration Between Pharmaceutical Companies and Diagnostic Firms** There is a growing trend of collaboration between pharmaceutical companies and diagnostic firms, which is enhancing the development and availability of companion diagnostics in South Korea. Such collaborations are key in ensuring that diagnostic tests are developed in tandem with new therapies, enabling healthcare providers to make informed treatment decisions. For instance, partnerships between companies like AstraZeneca and various biotechnology firms focus on creating diagnostic tests that correspond with their oncology drugs. This trend not only expands the diagnostic options available to physicians but also fosters a market environment conducive to high-value healthcare solutions, aligning with the objectives of the South Korea Companion Diagnostics Oncology Market. **South Korea Companion Diagnostics Oncology Market Segment Insights** **Companion Diagnostics Oncology Market Technology Insights** The South Korea Companion Diagnostics Oncology Market, particularly the Technology segment, is experiencing significant evolution, driven by advancements in precision medicine and the increasing focus on personalized treatment strategies. Next Generation Sequencing (NGS) stands out in this landscape due to its capacity to provide extensive genomic information, allowing for targeted therapies that align closely with a patient’s unique genetic makeup. This method is gaining traction in the oncology field, primarily because of its ability to uncover genetic mutations that could dictate the course of treatment. Furthermore, Polymerase Chain Reaction (PCR) remains a cornerstone in diagnostic techniques, noted for its high sensitivity and specificity in the detection of oncogenic biomarkers, thereby facilitating early diagnosis and treatment regimens. In Situ Hybridization (ISH) is recognized for its appealing ability to localize specific nucleic acid sequences within fixed tissues, greatly contributing to the understanding of tumor heterogeneity and the morphological context of genetic alterations. It plays a crucial role in the analysis of tumor samples, thereby assisting in therapeutic decisions tailored to individual patient profiles. Immunohistochemistry (IHC) holds significant importance as well, as it enables visualization of protein expression patterns in tumor tissues, which is critical in determining treatment efficacy and patient prognosis. The comprehensive insights provided through these technologies not only enhance diagnostic capabilities but also expand the avenues for treatment personalization, fostering an environment where targeted therapies are becoming a new standard in cancer care. As South Korea continues to invest in biopharmaceutical innovation and a robust health infrastructure, the synergy between these technologies within the Companion Diagnostics Oncology Market promises to enhance patient outcomes and drive future growth in personalized oncology treatments. The focus on integrating these technologies within clinical workflows exemplifies the country's commitment to advancing cancer diagnostics and treatment. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Companion Diagnostics Oncology Market Applications Insights** The Applications segment of the South Korea Companion Diagnostics Oncology Market plays a crucial role in enhancing cancer care through targeted therapies and personalized medicine. Therapeutic Monitoring is vital as it allows healthcare providers to assess the effectiveness of treatment, ensuring patients receive the most suitable therapy based on their unique genomic profiles. Patient Stratification helps in identifying the right patient groups likely to benefit from specific treatments, thereby increasing treatment success rates and minimizing adverse effects. Predictive Testing is significant in determining the likelihood of a patient developing a certain type of cancer or responding to a specific treatment, contributing to better preventive strategies and management plans. Disease Diagnosis significantly impacts early detection and accurate diagnosis, which are critical for successful treatment outcomes. With advancements in technology and increasing government support for innovative healthcare solutions, the South Korea Companion Diagnostics Oncology Market is expected to continue evolving, driven by these segments’ growing importance in the healthcare landscape. The focus on precision medicine is likely to enhance patient outcomes through tailored therapeutic approaches, which aligns with national healthcare initiatives aimed at improving cancer management in South Korea. **Companion Diagnostics Oncology Market****End-user****Insights** The South Korea Companion Diagnostics Oncology Market has shown promising development within the End-user segment, which includes Hospitals, Diagnostic Laboratories, Research Institutions, and Pharmaceutical Companies. Hospitals play a crucial role as they are often the first point of care for cancer patients, utilizing companion diagnostics to guide personalized treatment decisions. Diagnostic laboratories contribute significantly by providing accurate testing services that ensure tailored therapies are administered effectively. Research Institutions are pivotal in advancing the field, focusing on the discovery and validation of new biomarkers that enhance diagnostic capabilities. Pharmaceutical Companies leverage companion diagnostics to optimize drug development processes, ensuring that targeted therapies match the right patient populations. Overall, the collaboration between these sectors fosters innovation, improves patient outcomes, and drives the market's expansion, reflecting the growing importance of precision medicine in oncology within South Korea. The engagement of these diverse end users is a testament to their respective influences, challenges, and subsequent opportunities in the rapidly evolving companion diagnostics landscape in the region. **Companion Diagnostics Oncology Market Test Type Insights** The South Korea Companion Diagnostics Oncology Market, particularly in the Test Type segment, presents a diversified landscape characterized by various innovative testing methodologies. Genetic Tests are essential for identifying mutations relevant to targeted therapies, thereby enhancing personalized medicine in oncology. Protein Biomarker Tests, on the other hand, play a crucial role in the detection of specific proteins that may indicate the presence or progression of cancer, thus aiding in timely treatment decisions. MicroRNA Tests have gained attention for their potential to serve as biomarkers for cancer diagnosis and prognosis, providing insights into the molecular mechanisms of tumor development. Meanwhile, Pathological Analysis remains a foundational approach, encompassing tissue examination that is vital for accurate cancer diagnosis and staging. As South Korea positions itself as an advanced hub for medical technology, the demand for these tests is expected to grow steadily, driven by the increasing emphasis on precision medicine, patient-centric care, and ongoing Research and Development efforts in the oncology sector. Each of these testing methodologies plays a significant role in improving patient outcomes and optimizing treatment strategies across the South Korean healthcare landscape. **South Korea Companion Diagnostics Oncology Market Key Players and Competitive Insights** The South Korea Companion Diagnostics Oncology Market is a rapidly evolving segment that integrates molecular diagnostics with targeted therapies, enabling personalized treatment plans for cancer patients. This market is characterized by significant advancements in genomic technologies and major collaborations between diagnostic companies and pharmaceutical firms. The competitive landscape reflects a dynamic interplay of innovation, regulatory strategies, clinical partnerships, and an increasing emphasis on precision medicine. Companies are striving to enhance their offerings by focusing on technologies that facilitate the development of companion diagnostics, which are essential for determining patient eligibility for specific oncological therapies. As more healthcare providers adopt personalized medicine and increasingly sophisticated diagnostic tools, the market is expected to grow, with various players vying for leadership. Illumina, a key player in the South Korea Companion Diagnostics Oncology Market, has established a strong market presence through its innovative genomic sequencing platforms and extensive range of genomic assays. The company’s strengths include cutting-edge technology that allows for rapid and accurate genomic profiling, which is crucial for the development of effective cancer therapies. Illumina's commitment to research and development has resulted in advanced solutions that support oncologists in identifying the most suitable treatments, thereby improving patient outcomes. Furthermore, Illumina’s strategic partnerships with hospitals and research institutions within South Korea amplify its influence in the market, as these collaborations pave the way for real-world applications of genomic insights in oncology. Samsung Medical Center plays a significant role in the South Korea Companion Diagnostics Oncology Market by providing comprehensive cancer treatment and conducting advanced research in molecular diagnostics. The center is equipped with state-of-the-art facilities and employs a multidisciplinary approach, offering a range of key products and services including comprehensive genomic profiling and personalized cancer care plans. Samsung Medical Center’s strengths lie in its reputation for excellence in patient care, its collaborative efforts with leading pharmaceutical companies for the development of companion diagnostics, and its focus on innovation through research projects. The center has also engaged in strategic mergers and acquisitions to enhance its capabilities, thereby solidifying its position in the market. By fostering an environment that prioritizes precision oncology, Samsung Medical Center is well-poised to influence the landscape of companion diagnostics in South Korea. **Key Companies in the South Korea Companion Diagnostics Oncology Market Include:** - Illumina - Samsung Medical Center - Novartis - Merck - Bristol-Myers Squibb - Hanmi Pharmaceutical - Abbott Laboratories - Pfizer - GenoMediX - Amgen - Roche - OncoOne - LG Chem - Genexine - TiumBio **South Korea Companion Diagnostics Oncology****Market****Developments** Recent developments in the South Korea Companion Diagnostics Oncology Market reflect significant advancements and strategic movements among major players such as Illumina, Samsung Medical Center, Novartis, Merck, Bristol-Myers Squibb, Hanmi Pharmaceutical, Abbott Laboratories, Pfizer, GenoMediX, Amgen, Roche, OncoOne, LG Chem, and Genexine. Notably, in May 2023, Illumina announced a partnership with Samsung Medical Center to enhance genomic testing capabilities. As of June 2023, Merck and Bristol-Myers Squibb expanded their collaboration on cancer therapies, focusing on precision medicine, while Novartis and Amgen each reported increased investments in R&D for companion diagnostics. On the M&A front, LG Chem acquired a biotech firm in January 2023 to bolster its oncology pipeline. The South Korean Companion Diagnostics Oncology Market has seen a notable increase in valuation, currently estimated at USD 200 million, growing due to increased adoption of personalized medicine and robust government support for innovative therapies. Significant happenings in the market over the past two years include advancements in biomarker discovery and the integration of AI in clinical decision-making, which have streamlined diagnostics and improved patient outcomes. **South Korea Companion Diagnostics Oncology Market Segmentation Insights** **Companion Diagnostics Oncology Market Technology Outlook** - Next Generation Sequencing - Polymerase Chain Reaction - In Situ Hybridization - Immunohistochemistry **Companion Diagnostics Oncology Market Applications Outlook** - Therapeutic Monitoring - Patient Stratification - Predictive Testing - Disease Diagnosis **Companion Diagnostics Oncology Market End-userOutlook** - Hospitals - Diagnostic Laboratories - Research Institutions - Pharmaceutical Companies **Companion Diagnostics Oncology Market Test Type Outlook** - Genetic Tests - Protein Biomarker Tests - MicroRNA Tests - Pathological Analysis ## Market Drivers ### Regulatory Framework Enhancements The evolving regulatory framework in South Korea is positively influencing the companion diagnostics-oncology market. Recent updates to regulations have streamlined the approval processes for diagnostic tests, making it easier for companies to bring innovative products to market. The Ministry of Food and Drug Safety has implemented measures to expedite the review of companion diagnostics, which is likely to encourage more companies to invest in this sector. As a result, the market is expected to grow, with an anticipated increase in the number of approved diagnostic tests that can aid in the treatment of various cancers. ### Rising Awareness of Genetic Testing The growing awareness of genetic testing among patients and healthcare professionals is driving the companion diagnostics-oncology market. In South Korea, educational campaigns and initiatives by healthcare organizations are promoting the benefits of genetic testing in cancer diagnosis and treatment. This heightened awareness is leading to an increase in the number of patients seeking genetic testing services, which in turn supports the demand for companion diagnostics. It is estimated that the market could see a growth of 15% in the next few years as more patients understand the importance of genetic information in their treatment plans. ### Increased Investment in Cancer Research Investment in cancer research is significantly impacting the companion diagnostics-oncology market. In South Korea, both public and private sectors are allocating substantial funds to oncology research initiatives. This financial support is fostering the development of innovative diagnostic tools that can identify specific cancer types and their corresponding treatments. The government has committed over $200 million to cancer research in the past year, which is likely to enhance the capabilities of companion diagnostics. As research progresses, the market is expected to expand, with new diagnostic tests emerging that align with the evolving landscape of cancer treatment. ### Growing Demand for Personalized Medicine The shift towards personalized medicine is a key driver for the companion diagnostics-oncology market. In South Korea, healthcare providers are increasingly recognizing the value of tailored treatment approaches that consider individual genetic profiles. This trend is supported by a growing body of evidence indicating that personalized therapies can lead to improved patient outcomes and reduced healthcare costs. The market for companion diagnostics is expected to reach $500 million by 2027, reflecting the rising demand for targeted therapies. As patients and clinicians seek more effective treatment options, the role of companion diagnostics in identifying suitable therapies becomes increasingly critical. ### Technological Advancements in Diagnostics The companion diagnostics-oncology market is experiencing a surge due to rapid technological advancements in diagnostic tools. Innovations such as next-generation sequencing (NGS) and polymerase chain reaction (PCR) are enhancing the precision of cancer diagnostics. In South Korea, the integration of artificial intelligence in diagnostic processes is streamlining the identification of biomarkers, which is crucial for personalized treatment plans. The market is projected to grow at a CAGR of approximately 10% over the next five years, driven by these technological improvements. Furthermore, the increasing adoption of digital health solutions is facilitating better patient management and outcomes, thereby reinforcing the importance of companion diagnostics in oncology. ## Future Outlook The [Companion Diagnostics Oncology Market](https://www.marketresearchfuture.com/reports/companion-diagnostics-oncology-market-10422) is projected to grow at a 7.38% CAGR from 2025 to 2035, driven by advancements in personalized medicine, regulatory support, and increasing cancer prevalence. **New opportunities:** - Development of AI-driven diagnostic platforms for precision oncology - Expansion of partnerships with biopharmaceutical companies for co-development - Investment in telehealth solutions for remote patient monitoring and diagnostics By 2035, the market is expected to achieve substantial growth, reflecting its critical role in oncology. ## Segment Insights ### By Technology: Next Generation Sequencing (Largest) vs. Polymerase Chain Reaction (Fastest-Growing) In the South Korea companion diagnostics-oncology market, the distribution of market share among various technologies exhibits a clear hierarchy. Next Generation Sequencing (NGS) takes the lead, commanding a significant portion of the market. Meanwhile, Polymerase Chain Reaction (PCR) is gaining traction as an effective diagnostic tool, rapidly increasing its share due to its efficiency and reliability. Both In Situ Hybridization and Immunohistochemistry, while important, hold smaller portions of the overall market yet contribute to the diversity of technologies available. The growth trends in this market are driven by advancements in biotechnology and increasing demand for personalized medicine. NGS is favored for its high throughput and comprehensive genetic analysis, establishing itself as the dominant technology. In contrast, PCR is witnessing rapid adoption due to its simplicity and cost-effectiveness, making it the fastest-growing segment. The overall push for more accurate, efficient diagnostics continues to foster innovation across all technology categories. Technology: Next Generation Sequencing (Dominant) vs. Polymerase Chain Reaction (Emerging) Next Generation Sequencing (NGS) stands out as the dominant technology within the South Korea companion diagnostics-oncology market, renowned for its ability to analyze multiple genes simultaneously, providing extensive insights into tumor genomics. This comprehensive approach leads to better-targeted therapies and improved patient outcomes. On the other hand, Polymerase Chain Reaction (PCR) is recognized as an emerging technology, valued for its rapid results and ease of use. PCR's adaptability allows it to be applied across various diagnostic scenarios, driving its growth as healthcare providers increasingly seek efficient and reliable testing methods. Both technologies play crucial roles, each with unique strengths contributing to the enhancement of oncology diagnostics. ### By Applications: Therapeutic Monitoring (Largest) vs. Predictive Testing (Fastest-Growing) In the South Korea companion diagnostics-oncology market, the market share distribution among the applications reveals that Therapeutic Monitoring holds a significant portion due to its critical role in managing cancer treatments. Following closely are Patient Stratification and Disease Diagnosis, which contribute noteworthy shares as well. Predictive Testing, while currently smaller in market share, is emerging rapidly with a growing interest from stakeholders. Growth trends in this segment are driven by the increasing emphasis on personalized medicine, which enhances treatment efficacy. The rise in cancer prevalence has intensified the need for accurate diagnostics and monitoring. Innovations in molecular diagnostics and advancements in technology are encouraging the adoption of predictive testing, positioning it as a leading trendsetter in this segment, poised for substantial growth in the coming years. Therapeutic Monitoring (Dominant) vs. Predictive Testing (Emerging) Therapeutic Monitoring is characterized by its essential role in guiding oncology treatments, ensuring that therapies are optimized for individual patients. It provides insights into drug efficacy, allowing healthcare professionals to make informed decisions. This application is deeply entrenched in clinical practices, making it the dominant force in the market. On the other hand, Predictive Testing is gaining traction as an emerging application that assesses the likelihood of a patient responding to specific therapies. It leverages genetic and molecular profiling to inform treatment choices, fulfilling the demand for personalized care. As the healthcare landscape evolves, Predictive Testing is expected to gain momentum, driven by advancements in technology and an increasing demand for individualized treatment plans. ### By End User: Hospitals (Largest) vs. Pharmaceutical Companies (Fastest-Growing) In the South Korea companion diagnostics-oncology market, hospitals hold a significant market share due to their extensive patient interactions and diagnostic capabilities. They play a critical role in the adoption of companion diagnostics, as they directly influence treatment decisions and patient outcomes. Diagnostic laboratories also contribute positively, facilitating the testing processes but remain somewhat secondary to hospitals. Research institutions focus on innovation and advancement in diagnostics, while pharmaceutical companies are increasingly integrating companion diagnostics into their drug development processes. Growth trends in this segment indicate a robust increase in the demand for companion diagnostics across various end users. Hospitals are expected to continue being pivotal with their large patient populations. However, pharmaceutical companies are emerging as the fastest-growing segment, fueled by collaborations with diagnostic firms to enhance precision medicine initiatives and improve drug efficacy for oncology treatments. Hospitals: Dominant vs. Pharmaceutical Companies: Emerging Hospitals represent the dominant force in the South Korea companion diagnostics-oncology market due to their established infrastructures and capabilities in leading patient care. They are integral in utilizing diagnostic data to personalize oncology treatments. Pharmaceutical companies, on the other hand, are positioned as the emerging segment, rapidly developing partnerships with diagnostics firms to leverage personalized medicine. This collaboration allows them to create targeted therapies that align with specific patient profiles, thus driving innovation and enhancing the overall treatment landscape. As precision medicine gains traction, the roles of both hospitals and pharmaceutical companies evolve, leading to a more integrated approach to oncology care. ### By Test Type: Genetic Tests (Largest) vs. Protein Biomarker Tests (Fastest-Growing) In the South Korea companion diagnostics-oncology market, Genetic Tests hold the largest market share, driven by their advanced capabilities in identifying genetic mutations linked to various cancers. This segment's dominance is complemented by the increasing adoption of personalized medicine, which relies heavily on genetic insights for tailored treatment plans. On the other hand, Protein Biomarker Tests are rapidly gaining traction, recognized for their ability to provide critical information about tumor behavior and response to therapy, positioning them as the fastest-growing segment in this landscape. The growth trends in these segments reflect a broader shift towards precision medicine, where diagnostic tests are essential in informing treatment options. The rising prevalence of cancer in the region is driving investment and innovation in both Genetic Tests and Protein Biomarker Tests, with healthcare providers emphasizing the need for more accurate and early diagnostics. Research and development continue to focus on enhancing these tests' accuracy and efficiency, ensuring that they meet the demands of a changing healthcare environment. Genetic Tests (Dominant) vs. Protein Biomarker Tests (Emerging) The Genetic Tests segment stands as a dominant force in the South Korea companion diagnostics-oncology market, characterized by its utilization of advanced genomic technologies to detect mutations that are critical for effective treatment. These tests are pivotal for oncologists in selecting appropriate therapies, making them instrumental in the drive towards personalized medicine. Meanwhile, the Protein Biomarker Tests segment represents an emerging player, valued for its ability to assess protein expressions related to cancer. This segment is gaining momentum due to its capacity to provide insights into treatment responses, making it increasingly relevant in clinical decision-making. Both segments are set to play crucial roles in the evolution of oncology diagnostics, catering to the growing demand for personalized and effective cancer therapies. ## Competitive Benchmarking The companion diagnostics-oncology market in South Korea is characterized by a dynamic competitive landscape, driven by rapid technological advancements and an increasing emphasis on personalized medicine. Key players such as Roche (CH), Thermo Fisher Scientific (US), and Illumina (US) are at the forefront, leveraging their extensive research capabilities and innovative product offerings to capture market share. Roche (CH) focuses on integrating diagnostics with therapeutic solutions, enhancing its position through strategic partnerships and collaborations. Meanwhile, Thermo Fisher Scientific (US) emphasizes its broad portfolio of genomic and proteomic solutions, aiming to streamline workflows and improve patient outcomes. Illumina (US) continues to innovate in next-generation sequencing technologies, which are pivotal in companion diagnostics, thereby reinforcing its competitive edge.The business tactics employed by these companies reflect a concerted effort to optimize operations and enhance market presence. Localizing manufacturing and optimizing supply chains are prevalent strategies, allowing for greater responsiveness to regional demands. The market structure appears moderately fragmented, with several players vying for dominance, yet the collective influence of major companies shapes a competitive environment that is increasingly collaborative, particularly in research and development initiatives. In September Roche (CH) announced a strategic partnership with a leading South Korean biotechnology firm to co-develop a novel companion diagnostic test aimed at improving treatment outcomes for lung cancer patients. This collaboration is significant as it not only enhances Roche's local market presence but also aligns with the growing trend towards personalized medicine in oncology, potentially leading to improved patient stratification and treatment efficacy. In October Thermo Fisher Scientific (US) launched a new platform designed to integrate artificial intelligence (AI) into its diagnostic workflows, enhancing the accuracy and speed of genomic analyses. This move is indicative of the increasing importance of digital transformation in the companion diagnostics space, as AI capabilities can significantly reduce turnaround times and improve diagnostic precision, thereby meeting the evolving needs of healthcare providers. In August Illumina (US) expanded its collaboration with a prominent South Korean research institution to advance the development of genomic biomarkers for cancer therapies. This initiative underscores the critical role of strategic alliances in fostering innovation and enhancing the capabilities of companion diagnostics, as it allows for the pooling of resources and expertise to accelerate the discovery of novel biomarkers. As of November the competitive trends within the companion diagnostics-oncology market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are shaping the landscape, facilitating innovation and enhancing operational efficiencies. Looking ahead, it is likely that competitive differentiation will evolve, with a pronounced shift from price-based competition towards a focus on innovation, technological advancements, and supply chain reliability, ultimately driving better patient outcomes and more effective treatment strategies. ## Recent News & Developments Recent developments in the South Korea Companion Diagnostics Oncology Market reflect significant advancements and strategic movements among major players such as Illumina, Samsung Medical Center, Novartis, Merck, Bristol-Myers Squibb, Hanmi Pharmaceutical, Abbott Laboratories, Pfizer, GenoMediX, Amgen, Roche, OncoOne, LG Chem, and Genexine. Notably, in May 2023, Illumina announced a partnership with Samsung Medical Center to enhance genomic testing capabilities. As of June 2023, Merck and Bristol-Myers Squibb expanded their collaboration on cancer therapies, focusing on precision medicine, while Novartis and Amgen each reported increased investments in R&D for companion diagnostics. On the M&A front, LG Chem acquired a biotech firm in January 2023 to bolster its oncology pipeline. The South Korean Companion Diagnostics Oncology Market has seen a notable increase in valuation, currently estimated at USD 200 million, growing due to increased adoption of personalized medicine and robust government support for innovative therapies. Significant happenings in the market over the past two years include advancements in biomarker discovery and the integration of AI in clinical decision-making, which have streamlined diagnostics and improved patient outcomes. ## Report Scope | MARKET SIZE 2024 | 114.25(USD Million) | | --- | --- | | MARKET SIZE 2025 | 122.68(USD Million) | | MARKET SIZE 2035 | 250.04(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.38% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Roche (CH), Thermo Fisher Scientific (US), Abbott (US), Agilent Technologies (US), Illumina (US), Qiagen (DE), Myriad Genetics (US), Hologic (US), Guardant Health (US) | | Segments Covered | Technology, Applications, End User, Test Type | | Key Market Opportunities | Integration of advanced genomic technologies enhances precision medicine in the companion diagnostics-oncology market. | | Key Market Dynamics | Rising demand for personalized medicine drives growth in the companion diagnostics-oncology market in South Korea. | | Countries Covered | South Korea | ## Frequently Asked Questions **Q: What is the current valuation of the companion diagnostics-oncology market in South Korea?** A: The market valuation was $114.25 Million in 2024. **Q: What is the projected market size for the companion diagnostics-oncology market by 2035?** A: The projected valuation for 2035 is $250.04 Million. **Q: What is the expected CAGR for the South Korea companion diagnostics-oncology market during 2025 - 2035?** A: The expected CAGR during this period is 7.38%. **Q: Which companies are the key players in the South Korea companion diagnostics-oncology market?** A: Key players include Roche, Thermo Fisher Scientific, Abbott, Agilent Technologies, Illumina, Qiagen, Myriad Genetics, Hologic, and Guardant Health. **Q: What are the main technology segments in the companion diagnostics-oncology market?** A: Main technology segments include Next Generation Sequencing, Polymerase Chain Reaction, In Situ Hybridization, and Immunohistochemistry. **Q: What is the valuation range for the Next Generation Sequencing segment?** A: The valuation range for Next Generation Sequencing is $30.0 Million to $70.0 Million. **Q: What applications are driving the companion diagnostics-oncology market?** A: Driving applications include Therapeutic Monitoring, Patient Stratification, Predictive Testing, and Disease Diagnosis. **Q: What is the valuation range for Predictive Testing in the applications segment?** A: The valuation range for Predictive Testing is $35.0 Million to $80.0 Million. **Q: Who are the primary end users of companion diagnostics in South Korea?** A: Primary end users include Hospitals, Diagnostic Laboratories, Research Institutions, and Pharmaceutical Companies. **Q: What is the valuation range for the Protein Biomarker Tests segment?** A: The valuation range for Protein Biomarker Tests is $40.0 Million to $90.0 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-companion-diagnostics-oncology-market-50208*